![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Renal Conf: ELBASVIR/GRAZOPREVIR TREATMENT OF HCV INFECTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 4/5: CLINICAL, VIROLOGIC, AND HEALTH-RELATED QUALITY OF LIFE OUTCOMES IN THE C-SURFER STUDY
|
|
|
Reported by Jules Levin
53rd ERA-EDTA Congress in 2016,
53rd Congress of the European Renal Association
May 21-24 Vienna, Austria
A Bruchfeld, D Roth, P Martin, D R Nelson, S Pol, M-C Londoņo, S Wan, J M Arduino, M Robertson, B-Y Nguyen, J Wahl, E Barr, W Greaves
"HCV infection in patients with advanced chronic kidney disease is associated with an increased risk of death, accelerated loss of remaining kidney function and kidney transplant failure1-3
-Patients with HCV and stage 4/5 CKD have limited HCV treatment options due to lack of safety/efficacy data for DAAs in patients with CrCl <30mL/min and poor tolerability of regimens that include ribavirin" [from Jules: the earliest possible HCV treatment should be provided, delaying therapy can only increase risk for extra hepatic manifestations/comorbidities including kidney disease and increased risk for liver cancer (HCC). Medicaid & commercial therapy restrictions can be very harmful.]
![DDW1](../images/052716/052716-5/DDW1.gif)
![DDW2](../images/052716/052716-5/DDW2.gif)
![DDW3](../images/052716/052716-5/DDW3.gif)
![DDW4](../images/052716/052716-5/DDW4.gif)
![DDW5](../images/052716/052716-5/DDW5.gif)
![DDW6](../images/052716/052716-5/DDW6.gif)
![DDW7](../images/052716/052716-5/DDW7.gif)
![DDW8](../images/052716/052716-5/DDW8.gif)
![DDW9](../images/052716/052716-5/DDW9.gif)
![DDW10](../images/052716/052716-5/DDW10.gif)
![DDW11](../images/052716/052716-5/DDW11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|